Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice

This study aimed to investigate how amyloid pathology affects the functional aspects of neurotransmitter systems in Alzheimer's disease. APPswe/PS2 mice (21 months of age) and wild-type (WT) mice underwent positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). First, we obtained F-18-FDG and F-18-florbetaben PET scans to evaluate neuronal integrity and amyloid pathology. Second, F-18-FPEB and F-18-FMZ PET data were acquired to assess the excitatory-inhibitory neurotransmission. Third, to monitor the dopamine system, F-18-fallypride PET was performed. Amyloid PET imaging revealed that radioactivity was higher in the AD group than that in the WT group, which was validated by immunohistochemistry. In the cortical and limbic areas, the AD group showed a 25-27% decrease and 14-35% increase in the glutamatergic and GABAergic systems, respectively. The dopaminergic system in the AD group exhibited a 29% decrease in brain uptake compared with that in the WT group. A reduction in glutamate, N-acetylaspartate, and taurine levels was observed in the AD group using MRS. Our results suggest that dysfunction of the neurotransmitter system is associated with AD pathology. Among the systems, the GABAergic system was prominent, implying that the inhibitory neurotransmission system may be the most vulnerable to AD pathology.

Automated summary

This study aimed to investigate the impact of amyloid pathology on the functional aspects of neurotransmitter systems in Alzheimer's disease. The results revealed increased amyloid pathology in the AD group, as well as decreased glutamatergic and GABAergic systems and a reduction in the dopaminergic system. These findings suggest a connection between dysfunction of neurotransmitter systems and AD pathology.